In this article
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.
Pfizer
made one thing clear this week: It’s officially back in the obesity race.
The drugmaker is laser-focused on bringing to market treatments from its $10 billion acquisition of the obesity biotech Metsera. On Tuesday, it released promising phase two trial data on one injection, called PF′3944, that’s furthest along in development.
